Clinical Trial Update: Phase II Study of Everolimus Beyond Progression [Phase 2]

View source ↗

Summary

Phase II trial evaluating Everolimus beyond progression in breast cancer was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer
• Stage Iiia Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Emory University | Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-04-05